p27(kip1)-838C > A Single Nucleotide Polymorphism Is Associated With Restenosis Risk After Coronary Stenting and Modulates p27(kip1) Promoter Activity

Article

关键词: GENETIC RISK;    UPDATE 2007;    QUANTIFICATION;    EXPRESSION;    INHIBITORS;    THERAPY;    PROTEIN;    LENGTH;   

DOI  :  10.1161/CIRCULATIONAHA.108.842179

来源: SCIE

【 摘 要 】

Background-The cyclin-dependent kinase inhibitor p27(kip1) is a key regulator of smooth muscle cell and leukocyte proliferation in vascular disease, including in-stent restenosis. We therefore hypothesized that common genetic variations or single nucleotide polymorphisms in p27(kip1) may serve as a useful tool in risk stratification for in-stent restenosis. Methods and Results-Three single nucleotide polymorphisms concerning the p27(kip1) gene (-838C > A, rs36228499; -79C > T, rs34330; +326G > T, rs2066827) were determined in a cohort of 715 patients undergoing coronary angioplasty and stent placement. We discovered that the p27(kip1)-838C > A single nucleotide polymorphism is associated with clinical in-stent restenosis; the -838AA genotype decreases the risk of target vessel revascularization (hazard ratio, 0.28; 95% confidence interval, 0.10 to 0.77). This finding was replicated in another cohort study of 2309 patients (hazard ratio, 0.61; 95% confidence interval, 0.40 to 0.93). No association was detected between this end point and the p27(kip1)-79C > T and + 326G > T single nucleotide polymorphisms. We subsequently studied the functional importance of the -838C > A single nucleotide polymorphism and detected a 20-fold increased basal p27(kip1) transcriptional activity of the -838A allele containing promoter. Conclusions-Patients with the p27(kip1)-838AA genotype have a decreased risk of in-stent restenosis corresponding with enhanced promoter activity of the -838A allele of this cell-cycle inhibitor, which may explain decreased smooth muscle cell proliferation. (Circulation. 2009; 120: 669-676.)

【 授权许可】

Free